Myriad Genetics (MYGN) reported Q4 adjusted earnings late Monday of $0.03 per diluted share, down from $0.04 a year earlier.
Analysts polled by FactSet expected $0.03.
Revenue for the quarter that ended Dec. 31 was $210.6 million, up from $196.6 million a year earlier.
Analysts surveyed by FactSet expected $211.6 million.
The company expects a Q1 adjusted loss per share of $0.04 to $0.08 and 2025 adjusted EPS of $0.07 to $0.11, which it said is in line with its prior outlook. Analysts surveyed by FactSet expect a loss of $0.03 and earnings of $0.04, respectively.
The company expects Q1 revenue between $196 million and $204 million and continues to expect full-year revenue of $840 million to $860 million. Analysts polled by FactSet expect $206.6 million and $860.8 million, respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.